AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, B. A.
Right arrow Articles by Waisman, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, B. A.
Right arrow Articles by Waisman, H. A.
Agricola
Right arrow Articles by Smith, B. A.
Right arrow Articles by Waisman, H. A.

American Journal of Clinical Nutrition, Vol 24, 423-431, Copyright © 1971 by The American Society for Clinical Nutrition, Inc.

Adequate phenylalanine intake for optimum growth and development in the treatment of phenylketonuria

Barbara A. Smith M.S.1 and Harry A. Waisman M.D., Ph.D.1

1 From the Joseph P. Kennedy Jr. Memorial Laboratories, Department of Pediatrics, University of Wisconsin Medical Center, Madison, Wisconsin 53706

Early diagnosed PKU patients were divided into two groups according to whether their plasma phenylalanine levels had been maintained at less than 2 or between 3 and 10 mg/100 ml during the period of rapid brain development in early infancy. The physical growth and mental development of both groups were compared with standard values from normal children and with growth and development of their own unaffected siblings.

Infants whose plasma phenylalanine levels were below 2 mg/100 ml often did not maintain their original growth percentile standings and at 12 months of age ranked lower in percentile weight and height than their unaffected siblings. Patients whose plasma phenylalanine levels were between 3 and 10 mg/100 ml maintained growth percentile ratings similar to those of their unaffected siblings.

Patients in the more restricted group scored significantly (P < 0.05) below their unaffected siblings on learning tests, whereas there was no difference (P > 0.05) between scores of patients in the less restricted group and those of their unaffected siblings. A highly significant difference (P < 0.005) was found between the developmental scores of the two patient groups.

The results of this study demonstrate that the dietary phenylalanine required by PKU infants is the same as that minimum required by normal infants of the same age. It is recommended that the neonate with PKU receive an initial phenylalanine intake of 60 mg/kg body wt. From this, fine adjustments are made according to individual requirements for normal growth and in order to maintain plasma phenylalanine levels between 3 and 10 mg/100 ml, which the authors consider to be the safest range for optimum growth and development.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1971 by The American Society for Nutrition